AbbVie Analyst Ratings
Piper Sandler Maintains Overweight on AbbVie, Maintains $190 Price Target
Buy Rating Affirmed for AbbVie on Strong Aesthetics Market Position and Positive Sales Outlook
Cantor Fitzgerald Reiterates Overweight on AbbVie, Maintains $200 Price Target
AbbVie Analyst Ratings
AbbVie Analyst Ratings
HSBC Upgrades AbbVie to Buy, Announces $185 Price Target
Strong Financial Outlook and Strategic Initiatives Underpin Buy Rating for AbbVie
Analysts Are Bullish on These Healthcare Stocks: AbbVie (ABBV), Aerovate Therapeutics (AVTE)
AbbVie (ABBV.US) was first covered by Cantor Fitzgerald, which gave it an increase rating, with a target price of $200.00.
AbbVie Analyst Ratings
Buy Rating Affirmed: AbbVie's Promising Growth Trajectory and Financial Outlook
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), AbbVie (ABBV) and Establishment Labs Holdings (ESTA)
Daiwa Securities Adjusts Price Target on AbbVie to $171 From $190
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Molina Healthcare (MOH) and Cytokinetics (CYTK)
Hold Rating on AbbVie Amidst Humira Concerns and Biosimilar Competition Despite Strong Pipeline Prospects
Bank of Montreal, Canada: Maintaining the AbbVie (ABBV.US) rating, adjusted from superior to superior market rating, target price adjusted from $195.00 to $180.00.
AbbVie Analyst Ratings
BMO Capital Maintains Outperform on AbbVie, Lowers Price Target to $180
Barclays Adjusts Price Target on AbbVie to $187 From $195